Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PDS Biotechnology Corporation - Common Stock (NQ:PDSB)

1.173 -0.127 (-9.79%)
Delayed Quote Updated: 9:59 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PDS Biotechnology Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
PDSB Q1 2026 Earnings Transcript ↗
PDSB Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
PDS Biotechnology Q1 Earnings Call Highlights ↗
PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and... 
Via MarketBeat
Topics Earnings
PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5% ↗
Via Chartmill
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Insights into PDS Biotechnology's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Insights Ahead: PDS Biotechnology's Quarterly Earnings ↗
 
Via Benzinga
News headline image
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Q3 2025 Earnings Beat, Stock Surges 64% in Pre-Market ↗
PDS Biotech (PDSB) Q3 2025 earnings beat EPS estimates, sparking a major pre-market surge. The clinical-stage biotech also announced key progress for its lead cancer therapy. 
Via Chartmill
Topics Earnings
News headline image
A Look Ahead: PDS Biotechnology's Earnings Forecast ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval ↗
The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial. 
Via Stocktwits
News headline image
Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026 ↗
Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids. 
Via Stocktwits
News headline image
A Look at PDS Biotechnology's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
Uncovering Potential: PDS Biotechnology's Earnings Preview ↗
 
Via Benzinga
News headline image
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Narrower Q2 2025 Loss, Stock Rises on Clinical Progress ↗
PDS Biotechnology (PDSB) reported Q2 2025 EPS of -$0.21, beating estimates. Stock rose 8.13% pre-market as clinical progress, including ASCO presentations, boosts investor optimism. No revenue yet. 
Via Chartmill
News headline image
PDSB Loss Improves as Costs Drop ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish ↗
The company said the reduced losses were primarily due to decreased operating expenses. 
Via Stocktwits
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q2 2024 ↗
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024 ↗
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023 ↗
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.